[breadcrumb_custom]

Analyzing BioNexus Gene Lab Corp (NASDAQ: BGLC) Stock’s Performance and Trends for Investment

In the latest trading session, 23.06 million BioNexus Gene Lab Corp (NASDAQ:BGLC) shares changed hands as the company’s beta touched 1.81. With the company’s most recent per share price at $1.56 changing hands around $1.15 or 279.56% at last look, the market valuation stands at $27.75M. BGLC’s current price is a discount, trading about -1046.15% off its 52-week high of $17.88. The share price had its 52-week low at $0.31, which suggests the last value was 80.13% up since then. When we look at BioNexus Gene Lab Corp’s average trading volume, we note the 10-day average is 38780.0 shares, with the 3-month average coming to 71.28.

BioNexus Gene Lab Corp (NASDAQ:BGLC) trade information

Instantly BGLC is in green as seen in intraday trades today. With action 258.62%, the performance over the past five days has been green. The jump to weekly highs of 2.2400 added 279.56% to the stock’s daily price. The company’s shares are showing year-to-date upside of 194.34%, with the 5-day performance at 258.62% in the green. However, in the 30-day time frame, BioNexus Gene Lab Corp (NASDAQ:BGLC) is 231.91% up. Looking at the short shares, we see there were 93570.0 shares sold at short interest cover period of 1.87 days.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

BioNexus Gene Lab Corp (NASDAQ:BGLC)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 63.50% of BioNexus Gene Lab Corp shares while 0.89% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 2.45%. There are 0.89% institutions holding the BioNexus Gene Lab Corp stock share, with Virtu Financial LLC the top institutional holder. As of Sep 29, 2023, the company held 0.34% of the shares, roughly 59688.0 BGLC shares worth $80578.0.

Citadel Advisors Llc holds the second largest percentage of outstanding shares, with 0.29% or 51751.0 shares worth $69863.0 as of Sep 29, 2023.

With 23681.0 shares estimated at $31969.0 under it, the former controlled 0.13% of total outstanding shares.

On Key

Related Posts